TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02193126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trauma Affect Regulation: Guide for Education and Therapy (TARGET)
Description: The intervention is called the Trauma Affect Regulation: Guide for Education and Therapy (TARGET). TARGET is a manualized, psycho-educational intervention delivered in 10 - 12 sessions. TARGET is designed to address complex trauma and difficulties with emotional regulation and relational engagement that occur across a wide range of trauma-related difficulties, including trauma-related and behavioral symptoms. The full TARGET model consists of learning 7 essential core skills. These skills are called the FREEDOM steps: Focus, Recognize triggers, Emotion self-check, Evaluate thoughts, Define goals, Options, and Make a contribution.
Study: NCT01546675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skeletal Stabilization
Description: Upper Limb Prosthetic Socket hypothesized to increase skeletal stabilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skeletal Stabilization
Description: Upper Limb Prosthetic Socket hypothesized to increase skeletal stabilization
Study: NCT02786992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT05296707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The MIP/MEP value of the group that will receive inspiratory muscle training was determined and Threshold IMT training was given with 30%.~In the training, the subjects were asked to sit in a relaxed position with their upper chest and shoulders relaxed.~After the nose clip was attached, the children were asked to inhale and exhale by tightly closing the mouthpiece of the instrument with their lips.~A 30-minute training session was carried out for 6 weeks, with 10-15 repetitive breathing apparatus and 5-10 seconds rest breaks every day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Used routine medicine
Description: After the first evaluation was made, a second evaluation was made after 6 weeks of follow-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Used routine medicine
Description: After the first evaluation was made, a second evaluation was made after 6 weeks of follow-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: A healthy child compatible with the age and sex of the patient group was evaluated once.
Study: NCT04098562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LL37
Description: cream

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Wound Care
Description: Standard wound debridement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Wound Care
Description: Standard wound debridement
Study: NCT02773173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPP in colorectal laparoscopic surgery
Description: Deep neuromuscular blockade can only be reversed with sugammadex, so in the IPP group, it will be used as neuromuscular blocking agent and its effect will be reversed with sugammadex (4mg / kg) at the end of the surgery. During surgery: deep neuromuscular blockade (PTC 1-5), Protective ventilation strategy, Optimal position and Pre stretching as a tool to decrease intraabdominal pressure maintaining optimal workspace.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: SPP in colorectal laparoscopic surgery
Description: A depolarizing neuromuscular blocking will be used (as routine clinical practice at each center) to maintain moderate neuromuscular blockade and its effect will be reversed with anticholinesterase at the end of the surgery. During surgery: Moderate neuromuscular blockade ( TOF 2-4) , position to surgeon criteria, no prestretching and Protective ventilation. Fixed IAP (12mmHg).
Study: NCT03117998

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REMD-477
Description: Administered as repeated SC doses in subjects with Type 1 Diabetes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REMD-477
Description: Administered as repeated SC doses in subjects with Type 1 Diabetes

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Administered as a repeated SC doses in subjects with Type 1 Diabetes
Study: NCT03298477

Intervention type: DEVICE
Group type: OTHER
Intervention: Nellix® System
Description: Endovascular Abdominal Aortic Aneurysm Repair using the Nellix® System
Study: NCT02870829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: menaquinone-7
Description: Oral supplement given post dialysis 3x/week
Study: NCT00293059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)
Description: 2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placeboA blister card consists of 28 pills taken orally once a day for 28 days (one cycle)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to be taken orally daily.
Study: NCT00970762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg intubating dose
Description: Rocuronium 0.6 mg/kg intubating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg intubating dose
Description: Rocuronium 0.6 mg/kg intubating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg intubating dose
Description: Rocuronium 0.6 mg/kg intubating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg/kg intubating dose
Description: 0.9 mg/kg intubating dose of rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg/kg intubating dose
Description: 0.9 mg/kg intubating dose of rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg/kg intubating dose
Description: 0.9 mg/kg intubating dose of rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.1 mg/kg maintenance dose
Description: Rocuronium 0.1 mg/kg maintenance dose following the intubating dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.1 mg/kg maintenance dose
Description: Rocuronium 0.1 mg/kg maintenance dose following the intubating dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.15 mg/kg maintenance dose
Description: Rocuronium 0.15 mg/kg maintenance dose following the intubating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.15 mg/kg maintenance dose
Description: Rocuronium 0.15 mg/kg maintenance dose following the intubating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.2 mg/kg maintenance
Description: Rocuronium 0.2 mg/kg maintenance dose following the intubating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.2 mg/kg maintenance
Description: Rocuronium 0.2 mg/kg maintenance dose following the intubating dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vecuronium 0.1 mg/kg intubating dose
Description: Vecuronium 0.1 mg/kg intubating dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vecuronium 0.025 mg/kg maintenance dose
Description: Vecuronium 0.025 mg/kg maintenance dose following the intubating dose
Study: NCT03287895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support
Description: A two-part intervention to help patients make better decisions about CPR
Study: NCT02001064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care4Today v2.0 mobile application + electronic monitoring of adherence
Description: Care4Today mobile application will send automated medication alert messages to HIV-infected persons. The alert messages are customizable and automated, and real-time results are viewable within the application. The Care4Today intervention is designed to improve adherence to ART medications among HIV-infected persons who experience adherence difficulties over standard of care.
Study: NCT04188275

Intervention type: DIAGNOSTIC_TEST
Intervention: Periodic ARV7 and miRNA evaluation
Description: Determination of AR-V7 splice variants on circulating tumor cells and evaluation of circulating levels of miRNA by blood sample collection during PSA assessment at different time points along the treatment course (initiation, 8-weeks assessment, progression).
Study: NCT01390870

Intervention type: DRUG
Intervention: 5ARI or AB or Combination Therapy (5ARI + AB)
Description: 5ARI: Dutasteride or Finasteride; AB: Doxazosin, Silodosin, Tamsulosin, Terazosin, or Alfuzosin
Study: NCT04050657

Intervention type: OTHER
Group type: OTHER
Intervention: appointment interval
Description: To change the appointment interval for one group and keep the standard interval for the other group by measuring alignment duration, measured as days needed to align the teeth using full-arch fixed appliances

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: appointment interval
Description: To change the appointment interval for one group and keep the standard interval for the other group by measuring alignment duration, measured as days needed to align the teeth using full-arch fixed appliances
Study: NCT02498912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Production of Genetically-modified T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IP Catheter Insertion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells
Description: Patients who do not have sufficient CAR T cells for the assigned dose cohort will be treated in the cohort for which cells are available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: fludarabine dose 25-30 mg/m2 x 3 days
Study: NCT04247334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: 20 minutes of 2 milliamp transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: 20 minutes of 2 milliamp transcranial direct current stimulation
Study: NCT00501280

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview by telephone or on-site in language of choice (English or Spanish), 60 to 70 minutes to complete the mother's and the child participants' questionnaires

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview by telephone or on-site in language of choice (English or Spanish), 60 to 70 minutes to complete the mother's and the child participants' questionnaires
Study: NCT04469049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Description: MBCT is an evidence-based psychotherapy which combines mindfulness skills with cognitive therapy strategies.
Study: NCT03932305

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lutein
Description: Lutein is a common oral supplement that may have neuroprotective effect on the human retina

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo tablet
Study: NCT01809834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etafilcon A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stenfilcon A
Study: NCT00422812

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: Inhaled Staccato Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PCZ 5 mg
Description: Inhaled Staccato Prochlorperazine 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PCZ 7.5 mg
Description: Inhaled Staccato Prochlorperazine 7.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PCZ 10 mg
Description: Inhaled Staccato Prochlorperazine 10 mg
Study: NCT01519505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: INDIVIDUAL INTERVENTIONS They were programmed to come the nurse office three times (1 ½ -2 hours each). Individual intervention efforts outside of weight control and other intervention groups were also supported. In fact, this kind of intervention was similar to the group intervention but one-by-one participant subject. GROUP INTERVENTIONS Six-hour educational programme structured in 2 to 4 sessions with 5 to 15 participants. We called all participants to remind them their group schedule (date/hour). The methods used in the group intervention were variable depending on the experience of the manager, group member' s needs and skills available (empowerment). Results were based on motivation, support from the other members, peer support and positive feedback.
Study: NCT01397422

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADS-5102 (extended release amantadine HCl)
Description: Oral capsules to be administered once daily at bedtime, for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADS-5102 (extended release amantadine HCl)
Description: Oral capsules to be administered once daily at bedtime, for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADS-5102 (extended release amantadine HCl)
Description: Oral capsules to be administered once daily at bedtime, for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADS-5102 (extended release amantadine HCl)
Description: Oral capsules to be administered once daily at bedtime, for 8 weeks
Study: NCT02622529

Intervention type: OTHER
Intervention: Screening through questionnaires
Description: Distribution of Questionnaires to every participant within the single existent Arm at three times.
Study: NCT04127500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: dexmedetomidine
Study: NCT02893787

Intervention type: OTHER
Intervention: Speckle Tracking Echocardiography
Description: Echocardiography analyses

Intervention type: OTHER
Intervention: Speckle Tracking Echocardiography
Description: Echocardiography analyses
Study: NCT00072137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox-TRICOM Vaccine
Description: Given intravesically

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox-TRICOM Vaccine
Description: Given intravesically

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox GM-CSF Vaccine Adjuvant
Description: Given intravesically

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox GM-CSF Vaccine Adjuvant
Description: Given intravesically

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo cystectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo cystectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo cystectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03613376

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Class II compression stockings
Description: Patients in this group will use class II compression stocking continuously until next evening and then next 4 days during daytime
Study: NCT02284217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVD
Description: ICP monitoring will be done in parallel for both HS-1000 and ICP monitoring via an EVD device (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals will last from 30 minutes to 6 hours, continuously depending on the patient's clinical condition. Each such interval may occur three times a day or more depending on the clinical condition of the patient.
Study: NCT01307683

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindful Moms
Description: 8 weekly 2-hour sessions, 2 booster telephone sessions, and 1 postpartum booster session
Study: NCT02539745

Intervention type: OTHER
Intervention: Vitamin D receptor polymorphic analysis
Description: Vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis.

Intervention type: OTHER
Intervention: Vitamin D receptor polymorphic analysis
Description: Vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis.

Intervention type: OTHER
Intervention: Serum levels of 1a, 25-Dihydroxyvitamin D3
Description: Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay.

Intervention type: OTHER
Intervention: Serum levels of 1a, 25-Dihydroxyvitamin D3
Description: Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay.
Study: NCT03193775

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBV vaccine
Description: HBV vaccine which contains Purified HBsAg produced by recombinant DNA technology (Euvax-B, LG Life sciences, Korea) intramuscularly in deltoid region at three different time intervals (0, 1, 6 months).
Study: NCT03698110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: PUEDES program included eight hours in groups and activities to practice at home.
Study: NCT03883100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HQP1351
Description: 40 mg tablet, taken orally once every other day
Study: NCT01282853

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic biopsy
Description: endoscopic biopsy for rapid urease test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic biopsy
Description: endoscopic biopsy for rapid urease test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic biopsy
Description: endoscopic biopsy for rapid urease test
Study: NCT01986452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support
Study: NCT03698526

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Samsung Gear VR, Galaxy S8, Applied VR App
Description: Virtual Reality Experience

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Samsung Gear VR, Galaxy S8, Applied VR App
Description: Virtual Reality Experience
Study: NCT00353249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted cognitive behavioral therapy (CBT)
Description: Adapted CBT is a group treatment for PTSD and will occur two times per week for 4 weeks. The sessions will last 90-minutes and will be led by a therapist and co-therapist.
Study: NCT04613583

Intervention type: OTHER
Intervention: SAFeR fetuses
Description: NO active intervention performed.
Study: NCT03122691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabis
Description: Cannabis will be self-administered by study participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabis
Description: Cannabis will be self-administered by study participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabis
Description: Cannabis will be self-administered by study participants
Study: NCT03698526

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Samsung Gear VR, Galaxy S8, Applied VR App
Description: Virtual Reality Experience
Study: NCT02517801

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanin capsules
Description: Chronic intake of 2 capsules for 30 days (2x daily). Capsules with 80 mg of anthocyanins.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: Chronic intake of 2 capsules for 30 days (2x daily). 2 capsules devoid of anthocyanins.
Study: NCT01428505

Intervention type: RADIATION
Group type: OTHER
Intervention: [18F]PBR111
Description: radioligand to assess binding to TSPO
Study: NCT04302948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCV RNA screening
Description: The Cepheid Xpert testing requires a fingerstick to obtain blood spots which are then tested for HCV RNA. Results available within one to two hours, facilitating counseling for patients to link to care.
Study: NCT00108732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Vaccinia-TRICOM Vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study: NCT02576509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Specified Dose on Specified Days